Our results show that in newly diagnosed GBM, the expression of the predominantly expressed TGF-β1, but not TGF-β2, is significantly associated to tumor progression and survival and could thus impact the patient’s outcome. The gene discussed is TGFB1; the disease is glioblastoma.